Jason Haas, Chief Financial Officer at Syros Pharmaceuticals, Inc. (SYRS), bought 180,707 shares at $1.68 ($292K) on 2024-09-12, disclosed to the SEC on 2024-09-12.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Several strong factors at once. The rarest rating we give.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.55 | 35,363 | $55K | 18.7% |
| 2 | $1.55 | 35,363 | $55K | 18.7% |
| 3 | $1.58 | 19,293 | $30K | 10.4% |
| 4 | $1.68 | 45,344 | $76K | 26.0% |
| 5 | $1.68 | 45,344 | $76K | 26.0% |
| Total | $1.62 avg | 180,707 |
| $292K |
| 100% |
| Filing → |
| ODTX | BUY | 2026-05-11 | $20K | — | Filing → |
| SYRS | SELL | 2024-11-20 | $29K | — | Filing → |